Encompass Health Co. (NYSE:EHC – Get Rating) – Research analysts at Jefferies Financial Group dropped their Q3 2022 EPS estimates for Encompass Health in a research report issued on Wednesday, August 3rd. Jefferies Financial Group analyst B. Tanquilut now forecasts that the company will post earnings per share of $0.67 for the quarter, down from their prior forecast of $1.04. The consensus estimate for Encompass Health’s current full-year earnings is $3.02 per share. Jefferies Financial Group also issued estimates for Encompass Health’s FY2023 earnings at $3.17 EPS.
Other equities analysts also recently issued reports about the stock. Stephens lowered their target price on shares of Encompass Health from $78.00 to $74.00 and set an “overweight” rating on the stock in a report on Tuesday, June 21st. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Encompass Health from $80.00 to $62.00 in a report on Wednesday. Credit Suisse Group reduced their price objective on shares of Encompass Health from $83.00 to $82.00 and set an “outperform” rating for the company in a research report on Friday, June 10th. Royal Bank of Canada reduced their price objective on shares of Encompass Health from $85.00 to $82.00 in a research report on Wednesday, June 8th. Finally, Raymond James reduced their price objective on shares of Encompass Health from $70.00 to $65.00 and set a “strong-buy” rating for the company in a research report on Thursday. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $74.60.
Encompass Health Price Performance
Encompass Health (NYSE:EHC – Get Rating) last issued its earnings results on Monday, August 1st. The company reported $0.89 earnings per share for the quarter, missing analysts’ consensus estimates of $0.97 by ($0.08). The firm had revenue of $1.33 billion for the quarter, compared to analyst estimates of $1.34 billion. Encompass Health had a return on equity of 16.20% and a net margin of 6.22%. Encompass Health’s quarterly revenue was up 3.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.17 earnings per share.
Institutional Investors Weigh In On Encompass Health
A number of institutional investors have recently modified their holdings of EHC. Meeder Asset Management Inc. bought a new stake in shares of Encompass Health in the first quarter valued at about $33,000. Worth Asset Management LLC bought a new stake in shares of Encompass Health in the first quarter valued at about $35,000. Covestor Ltd bought a new stake in shares of Encompass Health in the fourth quarter valued at about $38,000. Allworth Financial LP boosted its position in shares of Encompass Health by 83.1% in the first quarter. Allworth Financial LP now owns 630 shares of the company’s stock valued at $45,000 after acquiring an additional 286 shares during the period. Finally, Rather & Kittrell Inc. bought a new stake in shares of Encompass Health in the fourth quarter valued at about $49,000. Institutional investors own 91.70% of the company’s stock.
Encompass Health Cuts Dividend
The firm also recently announced a quarterly dividend, which will be paid on Monday, October 17th. Stockholders of record on Monday, October 3rd will be given a $0.15 dividend. The ex-dividend date of this dividend is Friday, September 30th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 1.13%. Encompass Health’s payout ratio is presently 34.25%.
Encompass Health Company Profile
Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.
- Get a free copy of the StockNews.com research report on Encompass Health (EHC)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.